A comparison of repaglinide and glibenclamide in the treatment of type 2 diabetic patients previously treated with sulphonylureas

European Journal of Clinical Pharmacology

Volumn 55, Issue 3, 1999, Pages 165-171

  Landgraf, R ^a   Bilo, H J G ^b   Muller P G ^c  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b HOSPITAL DE WEEZENLANDEN   (Netherlands)

^c NOVO NORDISK A S   (Denmark)

Author keywords

Glibenclamide; Repaglinide; Type 2 diabetes

Indexed keywords

ANTIDIABETIC AGENT; C PEPTIDE; FRUCTOSAMINE; GLIBENCLAMIDE; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PROINSULIN; REPAGLINIDE; SULFONYLUREA DERIVATIVE;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL DRUG ADMINISTRATION; POSTPRANDIAL STATE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

BLOOD GLUCOSE; CARBAMATES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLYBURIDE; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PIPERIDINES; SULFONYLUREA COMPOUNDS;

EID: 0032983847     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002280050613     Document Type: Article

References (17)

1. 1. Yki-Järvinen H (1995) Role of insulin resistance in the patho-genesis of NIDDM. Diabetologia 38: 1378-1388
2. 2. Alzaid AA (1996) Insulin resistance in non-insulin-dependent diabetes mellitus. A review. Acta Diabetol 33: 87-99
3. 3. Kabadi UM, Kabadi MM (1995) Combination sulfonylurea and insulin therapy in diabetes mellitus. Compr Ther 21: 731-736
4. 4. Ligtenberg JJM, van Haeften TW, Links TP, Smit AF, Reitsma WD (1995) Clinical relevance of ATP-dependent potassium channels. Neth J Med 47: 241-251
5. 5. Mooradian AD (1996) Drug therapy of non-insulin-dependent diabetes mellitus in the elderly. Drugs 51: 931-941
6. 6. Gerich JE (1989) Oral hypoglycemic agents. N Engl J Med 321: 1231-1245
7. 7. Hatorp V, Oliver S, Su CAPF (1998) Bioavailability of repaglinide, a novel antidiabetic agent, administered orally in tablet or solution form or intravenously in healthy male volunteers. Int J Clin Pharm Therap 36: 636-641
8. 8. Frøkjær-Jensen J, Kofod H, Godtfredsen SE (1992) Mechanism of action of AG-EE 623 ZW, a novel insulinotropic agent. Diabetologia 35 [Suppl 1]: A116
9. 9. Fuhlendorff J, Rorsman P, Kofod H, Brand CL, Rolin B, MacKay P, Shymko R, Carr RD (1998) Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 47: 345-351
10. 10. European NIDDM Policy Group (1993) A desk-top guide for the management of non-insulin-dependent diabetes mellitus (NIDDM). 2nd ed. Brussels: International Diabetes Federation: 8
11. 11. Wolfenbüttel BHR, Nijst L, Sels JPJE, Menheere PPCA, Müller PG, Nieuwenhuijzen Kruseman AC (1993) Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 45: 113-116
12. 12. Van Gaal LF, Van Acker KL, Damsbo P, De Leeuw IH (1995) Metabolic effects of repaglinide, a new oral hypoglycaemic agent in therapy-naive type 2 diabetics. Diabetologia 38 [Suppl 1]: abstract 164
13. 13. Ceriello A (1998) The emerging role of postprandial hyperglycaemic spikes in the pathogenesis of diabetic complications. Diabetic Medicine 15: 188-193
14. 1c) to the risk of development and progression of retinopathy in the Diabetes Control and Complications Trial. Diabetes 44: 968-983
15. 15. Tronier B, Marbury TC, Damsbo P, Windfeld K (1995) A new oral hypoglycaemic agent, repaglinide, minimises risk of hypoglycaemia in well-controlled Type 2 diabetic patients. Diabetes 44 [Suppl 1]: abstract 261
16. 16. Harrower ADB (1996) Pharmacokinetics of oral anti-hyperglycaemic agents in patients with renal insufficiency. Clin Pharmacokinet 31: 111-119
17. 17. Profozic V, Babic D, Renar, I Rupperecht E, Skrabalo Z, Metelko Z (1993) Benzoic acid derivative hypoglycemic activity in non-insulin dependent diabetic patients. Diabetologia 38[Suppl 1]: abstract 701